EXPANDER-1试验:新型Urocross™扩张器系统治疗良性前列腺增生继发下尿路症状的初步研究
EXPANDER-1是一项国际、前瞻性、三臂、开放标签试验,纳入前列腺体积30-80cc、IPSS>13、Qmax<12mL/s等条件的50岁以上男性,评估Urocross Expander System植入治疗BPH继发LUTS的安全性与可行性。截至2021年5月24日,39例和22例男性分别成功植入和取出装置且无并发症,未观察到植入物结壳,装置及手术相关不良事件多为轻中度,报告3例SAE。结论认为该手术可行且安全,疗效信号强烈支持进一步评估。
要点
- Urocross Expander System植入和取出均成功且无并发症,未观察到植入物结壳。
- 装置及手术相关不良事件多为轻中度,报告3例SAE,仅1例植入后需导尿超过3天。
- IPSS、QoL、PVR、Qmax及性功能等临床参数均观察到改善。
核心结论
- 初步结果表明Urocross Expander System治疗BPH/LUTS是可行且安全的手术。
- 强烈的疗效信号支持进一步评估前列腺尿道扩张(PURE)手术。
- 早期几代前列腺植入物的生物相容性、迁移和结壳等负面特征可能已被克服。
研究设计与样本
- 国际、前瞻性、三臂、开放标签EXPANDER-1试验。
- 纳入50岁及以上男性,前列腺体积30-80cc,前列腺尿道长度20-60/80mm,IPSS>13,Qmax<12mL/s,PVR<250mL,QoL评分≥3。
- 患者预先分配植入物留置时间:Arm-1为1个月、Arm-2为6个月、Arm-3为12个月,取出后随访Arm-1至6个月、Arm-2和Arm-3至3年。
- 本文报告取出后6个月的结果,长期随访数据收集正在进行中。
主要发现
- 截至2021年5月24日,39例和22例男性(平均年龄65岁)分别成功植入和取出装置,无任何并发症。
- 未观察到植入物结壳病例。
- 装置及手术相关不良事件多为轻中度,报告3例SAE。
- 仅1例患者植入后需导尿超过3天。
- IPSS、QoL、PVR、Qmax及性功能等临床参数均观察到改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文仅报告取出后6个月的结果,长期随访数据收集仍在进行中。
- 初步结果,结论认为需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To demonstrate the safety and feasibility of the Urocross Expander System (formerly branded as XFLO Expander System), an implantable nitinol tissue expander to trea t patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Men of 50 years or older were eligible to participate in the international, prospective, three-arm, open-label EXPANDER-1 trial if they had a prostate volume between 30 and 80 cc, prostatic urethra length between 20 and 60/80 mm, international prostate symptom score (IPSS) > 13, peak urinary flow (Qmax) < 12 mL/s, post-void residual (PVR) urine volume < 250 mL and quality of life (QoL) score ≥ 3. Patients had pre-assigned implant indwell times (1, 6, and 12 months for Arm-1, Arm-2 and Arm-3 respectively) with follow-up through 6 months (Arm-1) and 3 years (Arm-2 and Arm-3) post-retrieval. RESULTS: Outcome from treated subjects with their 6-month post-retrieval will be presented in this manuscript, as data collection from longer-term follow-up is ongoing. As of May 24, 2021, 39 and 22 men (mean age: 65), respectively, had implants successfully deployed and retrieved without any complications. No cases of implant encrustation were observed. Device- and procedure-related adverse events were predominantly mild to moderate in severity. Three SAEs were reported. Only one patient required catheterization post-implant for more than three days. Improvements in clinical parameters such as IPSS, QoL, PVR and Qmax as well as sexual function were observed. CONCLUSIONS: Preliminary results demonstrate that the Urocross Expander System is a feasible and safe procedure for treating BPH/LUTS. A strong signal of efficacy justifies further evaluation of this PRostatic Urethral Expansion (PURE) procedure. Negative features of earlier generations of prostatic implants such as biocompatibility, migrations and encrustation have possibly been overcome.
引用
- Woo HH, Huang CP, Huang WJ, et al. The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Prostate Cancer Prostatic Dis. 2022. PMID: 35641601. doi:10.1038/s41391-022-00548-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。